Understanding potential adverse events (AEs) related to target modulation is crucial for the efficient derisking of your molecules. However, this process remains challenging, even with extensive resources from literature and public databases. In Vitro Safety Insight simplifies this by:
- Providing a clear overview of secondary pharmacology results and corresponding safety profiles
- Ranking and prioritization of compounds for better decision-making
- Saving time, money, and resources with streamline processes
- Improving early drug discovery stages, especially when combined with time-efficient target profiling.
In Vitro Safety Insight displays pharmacological results, identifies potential organs at risk and suggests follow-up assays. To give you a comprehensive view of safety, the tool includes:
- A spatial overview of the pharmacological data to support more informed decisions.
- A custom hazard metric to assess organs at risk.
- A heatmap that visualizes the compound screening results.
- Suggested follow-up panels
Organs at risk are determined using a custom hazard metric scoring system that combines secondary pharmacology data with target-AE associations from our database. The database is developed through a semi-automatic process that integrates public and proprietary information.
Figure 1: Highlights of hits and potential organ at risk consequently.
Figure 2: Heatmap to compare and help select the best compounds.
Cutting-Edge In Vitro and In Silico Technologies Under One Roof
By leveraging DiscoveryAI services, we enhance our established offerings with advanced computational technologies. The In Vitro Safety Insight tool facilitates fast data processing and predictive interpretation, enabling earlier and more informed decision-making in safety pharmacology during drug discovery. This strategic approach accelerates research while ensuring high-quality results. Through predictive analytics and data-driven insights, we streamline processes and provide more reliable, efficient solutions to meet our partners’ needs.
